In this week’s installment of our “How Does It Work?” video series, we explore Antibody Drug Conjugates. Monoclonal antibodies are highly versatile molecules that we can modify to generate new and improved cancer therapies. Here we have a type of modified antibody, known as an antibody drug conjugate, or ADC. The ADC contains two antigen …Read More >

#Research has explored the ways to extend the half-life of peptide drugs. One innovative way to achieve this is by fusing #therapeutic peptides to the Fc region of an antibody to create what is known as a peptibody. When the peptibody is naturally taken up by cells it binds to an Fc (antibody) receptor within …Read More >

WuXi Biology oligonucleotide capabilities Sequence design Knockdown effect incell lines and primary cells (transfection d f uptake) Splicing analysis Functional assays Other assays: Tm determination Cytotoxicity lmmunotoxicity Off-target effect “Humanized” mouse models Transgenic, HDI and AAV mouse models NHP models Short and longterm KD efficacy/ harmacology readouts GalNAc-ASGPR delivery system SPR screening Customized assays for …Read More >

WuXi Discovery Services supports all of your research needs, including target discovery, in vitro and in vivo pharmacology, translational research and clinical biomarker testing, to enable drug discovery for your target compound for pain. Full-scale molecular characterizations from gene/protein expression in vitro functional assays with validation of GPCR, Kinase and ion channel targets Selectivity profiling …Read More >

WuXi AppTec xenograft and syngeneic tumor models in rats and CD47-related in vitro assay platform

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platform. Integrated Chemistry and Biology Research Platform | From Discovery to Candidate Selection and Beyond